Summary There is no information available on the relation between response to chemotherapy and the high-risk phenotype assessed by uPA and/or PAI-1. The clinical situation of neoadjuvant chemotherapy provides a means of rapidly assessing the sensitivity of the primary tumour to cytotoxic drug regimens. The goal of the study was to assess prospectively the predictive value of PAI-1 for response to first-line chemotherapy. PAI-1 concentration was measured on hypertonic cytosolic extracts (0.4 M potassium chloride) by ELISA before chemotherapy on a drill biopsy sample of the tumour in 69 T2 and T3 breast cancer patients (median age 46 years). Oestrogen receptor (ER) (51% ER+), progesterone receptor (PR) (58% PR+), S-phase (median 4.0%) and ploidy were also assessed in the majority of cases. The clinical response to treatment was evaluated after four cycles of FAC or FEC regimen (5-fluorouracil, epidoxorubicin or doxorubicin and cyclophosphamide) (one cycle every 4th week). PAI-1 could be assayed in 29 post-chemotherapy surgical samples. The objective response rate (complete response plus partial response) was 59% (41 out of 69). PAI-1 expressed as gram of tissue (range 19-2370 ng g-1 tissue) was highly correlated (r = 0.98) to PAI-1 expressed as mg protein (range 0.5-68 ng mg-1 protein). No correlation between PAI-1 level and response could be observed, with any cut-off. The post-and pre-chemotherapy PAI-1 levels were correlated (r = 0.66). Of all biological parameters, only high S-phase (cut-off 5%) was slightly correlated (X2 = 3.91, P = 0.05) to response. These data suggest that PAI-1 is not a predictive marker of response to chemotherapy in breast cancer and that its level is not altered by neoadjuvant chemotherapy.
Neoadjuvant chemotherapy provides a means of rapidly evaluating the sensitivity of a primary tumour to cytotoxic drug regimens. In breast cancer, neoadjuvant chemotherapy is used to improve breast preservation, although no survival advantage has yet been demonstrated (Scholl et al, 1994) . It has been reported recently that breast tumour response to primary chemotherapy could predict local and distant control as well as survival (Scholl et al, 1995) . Predictive tests of tumour response should be developed to more accurately select patients who may or may not benefit from such therapy (Bonadonna et al, 1990) . In this respect, the measurement of S-phase fraction by flow cytometry (Remvikos et al, 1993) and detection of multidrug resistance (MDR) phenotype, before or during treatment, have recently emerged as promising predictive tests (Chevillard et al, 1996) . It has been reported that the lysosomal protease cathepsin D might be associated with chemoresistance (Namer et al, 1991) .
Urokinase plaminogen activator (uPA) is a proteolytic enzyme involved in processes leading to tumour invasion of surrounding tissues. Its activity during metastasis is regulated by an inhibitor, plasminogen activator inhibitor-I (PAI-1). Previous studies have shown that high levels of uPA and PAI-I are associated with poor prognosis in primary breast cancers (Grondahl-Hansen et al, 1993; Janicke et al, 1993; Bouchet et al, 1994; Duffy et al, 1996) . However, there is no information available on the relation between response to chemotherapy and the high-risk phenotype determined by uPA and/or PAI-1. Recently, Foekens et al (1995) have shown that the assay of uPA in primary breast tumours may be useful in predicting the overall response of metastatic disease to tamoxifen, patients with uPA-negative tumours exhibiting a better response.
The goal of this pilot study was to assess prospectively the predictive value of the expression levels of PAI-I before first-line neoadjuvant chemotherapy and the response to this treatment in a series of 69 patients with primary operable breast cancer.
MATERIAL AND METHODS Patients
Patients with operable tumours, 3 cm or more in size, with or without clinical node involvement, with a pathological diagnosis of invasive breast cancer established on a drill biopsy tumour sample and aged less than 70 years were eligible for neoadjuvant chemotherapy. Inflammatory, bilateral, locally advanced or metastatic breast cancer were exclusion criteria for this study. All patients received four cycles of neoadjuvant FEC or FAC chemotherapy regimen (5-fluorouracil, epidoxorubicin or doxorubicin and cyclophosphamide) before locoregional treatment. Chemotherapy courses were administered every 4 weeks. Tumour response was evaluated clinically and radiologically after 4 months of treatment. Responders were defined by either a complete response (CR, disappearance of clinically palpable disease) or partial response (PR, reduction of more than 50% of the product of the two largest tumour diameters). Stable disease was defined by no change in tumour size and progressive disease 537 (26) 29 (42) 3 (4) 55 (80) 12 (17) 2 (3) 7 (10) 30 (43) 28 (41) 4 (6) 35 (51) 32 (46) 2 (3) 40 (58) (Zajdela et al, 1987 ) and processed as previously described for S-phase analysis by flow cytometry (Remvikos et al, 1991) . Assays PAI-I concentration was measured by ELISA (American Diagnostica) on hypertonic (0.4 M potassium cholride) cytosolic extracts of the drill biopsy sample before chemotherapy and of the surgical sample after chemotherapy, as described previously (Romain et al, 1995 DNA flow cytometry DNA flow cytometry analysis was performed on the pretreatment fine-needle sample of the primary tumour according to a technique previously described (Remvikos et al, 1991) . At least 10 000 cell nuclei were analysed on a Facscan (Becton Dickinson, San Jose, CA, USA) equipped with a doublet discrimination module. DNA histograms with a coefficient of variation (CV) > 6% for the GIG, classified as DNA diploid. A DNA index lower than 0.9 or higher than 1.1 could be distinguished from a diploid marker peak, and the tumours with such an index were classified as DNA aneuploid (Hedley et al, 1993) . The S-phase fraction (SPF) was derived using the Cellfit software (Beckton Dickinson, San Jose, CA, USA), including background subtraction. S-phase could be reliably derived for 48 patients (70%), the other 21 cases displaying complex DNA histograms (debris, multiploidy, CV greater than 6%).
Histological prognostic grade
Histological grade (SBR) was scored according to Scarff, Bloom and Richardson (Bloom and Richardson, 1957) .
Statistical analysis
The chi-square test (with Yates' correction when appropriate) was used for comparison of 2 x 2 tables. Linear regression was used for the correlation analysis of quantitative data (Figures 1 and 3) . The Mann-Whitney non-parametric test (Statistica) was used to compare responders to non-responders according to PAI-1 concentrations (Figure 2 ).
RESULTS
The objective response rate after four courses of neoadjuvant chemotherapy was 59% (41 out of 69). (range 0.5-68, mean 12.0 ± s.d. 12.8). Because of the high correlation (r = 0.98) (Figure 1 ) between the two modes of expression, the PAI-1 levels expressed in ng g-tissue were used for bioclinical correlations, allowing a greater number of cases to be analysed.
No relation between PAI-I level and response to chemotherapy could be observed (P = 0.66 by Mann-Whitney non-parametric test). Medians of PAI-I values were not statistically different between responders and non-responders (Figure 2) .
The post-and pre-chemotherapy PAI-1 levels were compared in 29 patients. They were significantly correlated (r = 0.66) ( Figure  3 ). The few variations observed were not correlated with response.
The association of different prognostic factors (age, hormonal status, tumour size, nodal status, SBR, ER, PR, S-phase) with clinical response was studied. Only high S-phase (cut-off 5%) was slightly correlated (%2 = 3.91, P = 0.05) with clinical response. Sphase was 2 5% in 15 out of 28 responders (54%) vs 5 out of 20 (25%) non-responders. There was no correlation between S-phase and PAI-I (r = 0.05).
DISCUSSION
Resistance to chemotherapy is a major clinical issue in the treatment of cancer. To achieve a more effective chemotherapeutic treatment of breast cancer patients in the future, it is essential to define reliable indicators of response to treatment in individual patients (Clark, 1994) .
Resistance to certain drugs has been associated with an overexpression of the multidrug resistance gene (MDR1), but the induction of MDRJ may be secondary to chemotherapy treatment and does not preclude an initial response to these same drugs (Chevillard et al, 1996) . Tumours with c-erbB-2 (HER2/neu) overexpression have also repeatedly shown not to benefit from standard adjuvant chemotherapy but could benefit from chemotherapy dose intensification (Muss et al, 1994) . Overexpression of GST2t, frequently coamplified with members of the fibroblast growth factor family, has equally been linked with a poor outcome despite standard treatment (Morrow and Cowan, 1993) . In the present study, of 69 patients receiving FAC or FEC neoadjuvant chemotherapy for breast cancer, we failed to find any correlation between PAI-I concentration in the tumour and chemoresistance. In addition, in 29 patients for whom pre-and post-chemotherapy tissue samples were available, the post-treatment PAI-1 tissue concentration was similar to the pretreatment concentration.
Fine-needle aspirates and drill biopsies ('tru-cuts' in some instances) allow access to tumour material before treatment and can thus be used for the assay of biological parameters potentially predictive of response to treatment. In the present study, PAI-I was assayed on a drill biopsy, which yields tissue material (including stroma), rather than on fine-needle aspirate, which provides mainly epithelial cells, as PAI-I is thought to be largely expressed by stromal cells (Duffy, 1996) and its prognostic value has been established on whole tissue samples.
Whether PAI-I assay on a drill biopsy is representative of the whole tumour may be questioned and we were not able, for ethical reasons, to test the reproducibility of the assay on different drill biopsy samples from the same patient. Previous experience (Magdelenat et al, 1983) with ER and PR assays supports the hypothesis that assays on drill biopsies accurately reflect the whole tumour status, at least for epithelial cell-associated parameters.
There are few studies in the literature that relate tumour protease expression to response to systemic treatment. Preliminary data suggest that high levels of uPA correlate with a lack of response to hormonal therapy in patients with advanced breast cancer (Foekens et al, 1995; Duffy, 1996) . Cathepsin D, a serine protease generally overexpressed in breast cancer cells under oestrogen stimulation in ER-positive cells and constitutively overexpressed in ER-negative cells, has been shown to be associated with increased risk of developing metastasis (Rochefort, 1992) . Adjuvant tamoxifen was found beneficial only to node-positive, progesterone receptor-positive breast cancers with high cathepsin D content (Ferno et al, 1994) . Namer et al (1991) suggested that elevated cathepsin D could be associated with resistance to chemotherapy.
The correlation between S-phase and clinical response to neoadjuvant chemotherapy in this study is in keeping with previous ones showing that the less breast carcinomas proliferate the more resistant they are. In a previous study of 60 patients, we observed that the pretreatment S-phase fraction was correlated with regression of the tumour mass after the administration of neoadjuvant chemotherapy (Remvikos et al, 1989) . Cell cycle modifications analysed by flow cytometry during neoadjuvant chemotherapy, most frequently conceming S-phase and G2M accumulation, were correlated with the efficacy of cytotoxic chemotherapy in a series of 71 patients .
In conclusion, the intratumoral PAI-I level was not significantly modified by four cycles of neoadjuvant FAC or FEC and was not predictive of response to these chemotherapy regimens in T2-T3 primary breast cancer.
